Provider file · new entrant · press-cited
CoreAge Rx: the file as of August 17, 2026
CoreAge Rx appears in August 2026 press coverage with flat annual pricing of $99/month compounded semaglutide and $149/month tirzepatide, no membership or hidden fees claimed, and U.S. board-certified physician review described. The capture tier matters: these figures come from promotional press coverage rather than a direct capture of the provider’s own checkout — one rung below self-published, two below on-record, three below audited. Listed for completeness, dated, and held at the door.
What would move the file
A direct capture of the provider’s published pricing pages (upgrading press-cited to on-record), then the standard walk: all-in confirmation, dose-proof language in writing, named pharmacy with verifiable licensure, exit terms. The claimed numbers would compute to ~$80–$89 per expected point — podium-adjacent — which is precisely why the verification bar stays high.
Open files
Direct pricing capture · pharmacy identity · dose behavior · refund terms · state coverage. Outbound link withheld until a direct capture exists, per linking policy.
Standing rules apply: compounded products are not FDA-approved; trial certificates belong to the brands; tier upgrades require the same audit the anchor passed, and corrections@ outranks this page with dated evidence. Field context: the cost index · tirzepatide value board · semaglutide value board.
No outbound link yet — pending direct capture of the provider’s own pages.